Radiotherapy after surgery has lasting benefits for prostate cancer patients

October 18, 2012

New research confirms that giving radiotherapy immediately after surgery to remove the prostate has long-term benefits for preventing the biochemical progression of the disease. After 10 years, 61 percent of men who received immediate radiotherapy treatment remained disease free compared with 38 percent who did not, according to the follow-up of the randomized EORTC trial 22911 published Online First in The Lancet.

"These long-term results reassure us of the continued benefit and safety of radiation therapy after for a large proportion of men with locally advanced or high-risk prostate cancer", explains Michel Bolla from the Centre Hospitalier Universitaire A Michallon in France who led the research. "They also suggest that younger patients and those with positive surgical margins are most likely to benefit from immediate radiotherapy, whereas in (aged 70 years plus) it could have detrimental effects."

Worldwide, prostate cancer is the second most common cancer in men after . One of the main treatments is removal of the prostate, but for patients whose cancer has spread beyond the prostate the risk of recurrence can be 10%, and a course of radiotherapy is often prescribed to improve outcomes.

Bolla and colleagues followed 1005 patients with high-risk for more than 10 years to examine the effect of immediate postoperative radiotherapy (given within 4 months of surgery) versus watchful waiting until first signs of .

Even after 10 years, men given immediate radiotherapy after surgery still had significantly better biochemical progression-free survival compared with those who were only monitored, with no significant difference in severe toxicity. They also had substantially better local control and so were less likely to need hormonal therapy which can have side effects after prolonged use.

But in contrast to initial (5 year) results, clinical progression-free survival (where the disease has not spread to other sites) was not significantly improved with immediate radiation therapy after 10 years, and radiotherapy had no effect on the 10-year rates of distant cancerous spread or overall survival.

Writing in a linked Comment, Jason A. Efstathiou from Massachusetts General Hospital in Boston discusses whether there is enough evidence to discern who should and should not receive after surgery and the best time to start treatment, writing that: Ultimately, the decision to treat needs multidisciplinary input. When surgery has probably not cured a patient, prospective data still support postoperative radiation. The onus is on the uro-oncology team (surgical, radiation, and medical) to discuss postoperative radiation with the patient, address optimal timing of initiation when it is used, and to provide justification when it is not."

Explore further: Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients

More information: Paper online: www.thelancet.com/journals/lan … (12)61608-0/abstract

Related Stories

Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients

May 2, 2011
Some studies have shown that blood-thinning medications, such as aspirin, can reduce biochemical failure––cancer recurrence that is detected by a rising prostate-specific antigen (PSA) level––the risk ...

More aggressive treatment not necessary for men with a family history of prostate cancer

October 5, 2011
Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.